title: Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.
abstract: BACKGROUND
  Vitamin D receptor activator (VDRA) therapy has been shown to be associated with reduced mortality rates in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT). However, differences between VDRAs in their ability to reduce both all-cause and cardiovascular-related mortality rates are not yet fully elucidated.
  
  
  METHODS
  The objective of the current analysis was to determine the effect of VDRA therapy on mortality in an Italian dialysis population, observed prospectively every 6 months for 18 months. Patients were investigated for all-cause and cardiovascular-related mortality risk adjusted for various demographic, clinical, and/or SHPT treatment variables.
  
  
  RESULTS
  The cumulative probabilities of all-cause and cardiovascular-related mortality were lower for patients who received any VDRA treatment compared with those who did not (p < 0.001) regardless of all measured variables. Additionally, patients who received paricalcitol and/or cinacalcet (with or without VDRAs) compared with calcitriol showed a significant improvement in both all-cause and cardiovascular-related mortality (p < 0.001). Cinacalcet with or without VDRAs was not associated with a further decrease of mortality hazard ratios compared with paricalcitol monotherapy.
  
  
  CONCLUSIONS
  VDRA therapy (associated or not with cinacalcet) was associated with improved survival in dialysis patients, independent of demographic and clinical variables.
authors.affiliation: Nephrology Unit, University of Milan, Milan, Italy. diego.brancaccio@tiscalinet.it
authors.forename: Diego
authors.initials: D
authors.lastname: Brancaccio
authors.forename: Mario
authors.initials: M
authors.lastname: Cozzolino
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Cannella
authors.forename: Piergiorgio
authors.initials: P
authors.lastname: Messa
authors.forename: Mario
authors.initials: M
authors.lastname: Bonomini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Cancarini
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Caruso
authors.forename: Carmelo
authors.initials: C
authors.lastname: Cascone
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Costanzo
authors.forename: Umberto
authors.initials: U
authors.lastname: di Luzio Paparatti
authors.forename: Sandro
authors.initials: S
authors.lastname: Mazzaferro
mesh_terms: D000368:Aged; D002117:Calcitriol / Q000008:administration & dosage / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D000069449:Cinacalcet; D004872:Ergocalciferols / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D007558:Italy; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D016017:Odds Ratio; D011446:Prospective Studies; D006435:Renal Dialysis; D012307:Risk Factors; D015996:Survival Rate; D014815:Vitamins / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D004872:Ergocalciferols; D009281:Naphthalenes; D014815:Vitamins; C084656:paricalcitol; D002117:Calcitriol; D000069449:Cinacalcet